Stocks · Health care · Pharmaceutical Preparations

Aktis Oncology, Inc.

AKTS
United States Fiscal year ends December CIK 0002035832 Results filed 13 Aug 2026

What the insiders did Net buying

Insider
Date
Role
Action
Shares
Price
Amount
Akos Czibere
23 Sep 2026
Chief Medical Officer
Sold after exercise
7,401
$21.03
$155.65K
Akos Czibere
23 Sep 2026
Chief Medical Officer
Sold after exercise
5,099
$20.19
$102.97K
Ken Herrmann
20 Jul 2026
Director
Sold after exercise
1,350
$24.56
$33.16K
Ken Herrmann
20 Jul 2026
Director
Sold after exercise
3,506
$24.56
$86.12K
Ken Herrmann
17 Jul 2026
Director
Sold after exercise
3,065
$25.21
$77.26K
Akos Czibere
8 Jul 2026
Chief Medical Officer
Sold after exercise
4,371
$28.71
$125.48K
Akos Czibere
8 Jul 2026
Chief Medical Officer
Sold after exercise
30,829
$27.95
$861.74K
Akos Czibere
8 Jul 2026
Chief Medical Officer
Sold after exercise
14,800
$27.13
$401.48K
Shulamit Ron-Bigger
8 Jul 2026
Chief Operating Officer
Sold after exercise
4,200
$28.75
$120.74K
Shulamit Ron-Bigger
8 Jul 2026
Chief Operating Officer
Sold after exercise
30,000
$27.94
$838.14K
Shulamit Ron-Bigger
8 Jul 2026
Chief Operating Officer
Sold after exercise
15,800
$27.13
$428.68K
Helen Susan Kim
12 Jan 2026
Director
Buy indirect
22,545
$18.00
$405.81K
Helen Susan Kim
12 Jan 2026
Director
Buy indirect
812,455
$18.00
$14.62M
Vida Ventures II, LLC
12 Jan 2026
10% owner
Buy indirect
22,545
$18.00
$405.81K
Vida Ventures II, LLC
12 Jan 2026
10% owner
Buy indirect
812,455
$18.00
$14.62M
EcoR1 Capital, LLC
12 Jan 2026
Director
Buy indirect
144,443
$18.00
$2.60M
EcoR1 Capital, LLC
12 Jan 2026
Director
Buy indirect
2,077,779
$18.00
$37.40M
Ansbert Gadicke
12 Jan 2026
10% owner
Buy indirect
1,112,777
$18.00
$20.03M
Mpm Bioventures 2018, L.p.
12 Jan 2026
10% owner
Buy indirect
1,112,777
$18.00
$20.03M
Todd Foley
12 Jan 2026
Director
Buy indirect
232,870
$18.00
$4.19M

What was left out

Form 4 filings counted 13
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 4
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 11
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 34,344,412
History held since 12 Jan 2026